<DOC>
	<DOCNO>NCT00794586</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 2 dose combination fosfomycin/tobramycin inhalation ( FTI ) , follow 28-day course Aztreonam Inhalation ( AZLI ) patient cystic fibrosis Pseudomonas aeruginosa lung infection .</brief_summary>
	<brief_title>Study Evaluating Fosfomycin/Tobramycin Inhalation Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection</brief_title>
	<detailed_description>Gilead develop broad spectrum combination antibiotic ( FTI ) consist fosfomycin ( antibiotic activity gram-positive gram-negative bacteria ) tobramycin ( aminoglycoside antibiotic potent gram-negative activity ) treatment patient CF . FTI offer potential option treatment CF lung infection . It important note concentration tobramycin FTI low approve dose inhaled tobramycin alone , thereby demonstrate potential FTI minimize long-term toxicity repeat exposure aminoglycosides like tobramycin . This study evaluate safety efficacy 2 dose combination fosfomycin/tobramycin inhalation ( FTI ) , follow 28-day course Aztreonam Inhalation ( AZLI ) patient cystic fibrosis Pseudomonas aeruginosa lung infection .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Males female age 18 year old Patients CF diagnose one following : Documented sweat chloride great equal 60 mEq/L quantitative pilocarpine iontophoresis test , OR Documented sweat sodium great equal 60 mmol/L , OR Abnormal nasal potential difference , OR Two wellcharacterized genetic mutation CF transmembrane conductance regulator ( CFTR ) gene , AND Accompanying symptom characteristic CF Documented presence PA expectorate sputum throat swab culture Visit 1 OR document PA 2 expectorate sputum throat swab culture within 12 month prior Visit 1 ; one previous PApositive culture must within 3 month prior Visit 1 Patients must able provide write informed consent prior study related procedure FEV1 great equal 25 % less equal 75 % predict Visit 1 Ability perform reproducible pulmonary function test Chest radiograph Visit 1 without significant acute finding ( e.g. , infiltrate [ lobar diffuse interstitial ] , pleural effusion , pneumothorax ) ; chest radiograph , CT , MRI obtain within 90 day prior Visit 1 without acute finding significant intercurrent illness ; chronic , stable finding ( e.g. , chronic scar atelectasis ) allow . Current use oral corticosteroid dos exceed equivalent 10 mg prednisone day 20 mg prednisone every day History sputum throat swab culture yield B. cepacia previous 2 year Current requirement daily continuous oxygen supplementation requirement 2 L/minute night Administration investigational drug device within 28 day Visit 1 within 6 halflives investigational drug ( whichever longer ) Known local systemic hypersensitivity monobactam antibiotic Known allergies/intolerance tobramycin aminoglycosides Known allergies/intolerance fosfomycin Inability tolerate inhalation short act beta2 agonist Changes initiation chronic azithromycin treatment within 14 day prior Visit 1 Administration antipseudomonal antibiotic inhalation , IV , oral route within 14 day prior Visit 1 Changes antimicrobial , bronchodilator ( BD ) , corticosteroid , hypertonic saline , dornase alfa medication within 7 day prior Visit 1 Changes physiotherapy technique schedule within 7 day prior Visit 1 History lung transplantation Abnormal renal hepatic function serum chemistry Visit 1 , define : AST , ALT &gt; 3 time upper limit normal range ( ULN ) Creatinine &gt; 1.5 time ULN Positive pregnancy test Visit 1 ; woman childbearing potential test Female patient childbearing potential lactating ( opinion investigator ) practice acceptable method birth control ; female patient utilize hormonal contraceptive birth control method must use method least 3 month study dose Any serious active medical psychiatric illness , opinion investigator , would interfere patient treatment , assessment , compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>inhale antibiotic</keyword>
	<keyword>antipseudomonal antibiotic</keyword>
	<keyword>tobramycin</keyword>
	<keyword>fosfomycin</keyword>
	<keyword>lung infection</keyword>
	<keyword>pseudomonal infection</keyword>
	<keyword>FTI</keyword>
</DOC>